Rick A. Vreman
Impact in
- Economics and Econometrics top 2%
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical Economics and Policy
- Economic and Financial Impacts of Cancer
Papers in
-
- Health Systems, Economic Evaluations, Quality of Life 34
- Pharmaceutical Economics and Policy 19
-
- Biomedical Ethics and Regulation 5
- Co-authors
- Wim Goettsch (33 shared papers)Aukje K. Mantel‐Teeuwisse (21 shared papers)Hubert G. M. Leufkens (13 shared papers)Anke M. Hövels (9 shared papers)Aaron S. Kesselheim (2 shared papers)Joris C. Verster (2 shared papers)Berend Olivier (1 shared paper)Suzanne de Klerk (2 shared papers)
- Journals
- Value in Health (8 papers)International Journal of Technology Assessment in Health Care (7 papers)BMJ Open (3 papers)Drug Discovery Today (3 papers)Clinical Pharmacology & Therapeutics (3 papers)
- Partner nations
- NetherlandsUnited StatesUnited Kingdom
In The Last Decade
Rick A. Vreman
52 papers receiving 713 citations
Peers
Comparison fields: 5 of 104
- Economics and Econometrics 344
- Genetics 25
- Family Practice 4
- Physiology 57
- Pharmacology 19
Countries citing papers authored by Rick A. Vreman
This map shows the geographic impact of Rick A. Vreman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rick A. Vreman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rick A. Vreman more than expected).
Fields of papers citing papers by Rick A. Vreman
This network shows the impact of papers produced by Rick A. Vreman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rick A. Vreman. The network helps show where Rick A. Vreman may publish in the future.
Co-authors
The 25 scholars most cited alongside Rick A. Vreman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 75 | |
| 2 | 2014 | 72 | |
| 3 | 2020 | 54 | |
| 4 | 2017 | 51 | |
| 5 | 2018 | 44 | |
| 6 | 2020 | 39 | |
| 7 | 2020 | 27 | |
| 8 | 2022 | 27 | |
| 9 | 2020 | 24 | |
| 10 | 2021 | 23 | |
| 11 | 2021 | 20 | |
| 12 | 2019 | 17 | |
| 13 | 2021 | 17 | |
| 14 | 2021 | 15 | |
| 15 | 2019 | 15 | |
| 16 | 2020 | 14 | |
| 17 | 2020 | 13 | |
| 18 | 2022 | 13 | |
| 19 | 2022 | 13 | |
| 20 | 2023 | 12 |
About Rick A. Vreman
Rick A. Vreman is a scholar working on Economics and Econometrics, Physiology, Pediatrics, Perinatology and Child Health, General Health Professions and Statistics and Probability, having authored 54 papers that have together received 727 indexed citations. Recurring topics across this work include Health Systems, Economic Evaluations, Quality of Life (34 papers), Pharmaceutical Economics and Policy (19 papers), Biomedical Ethics and Regulation (5 papers), Pharmaceutical studies and practices (4 papers), Healthcare cost, quality, practices (3 papers), Vaccine Coverage and Hesitancy (2 papers), Pharmaceutical industry and healthcare (2 papers) and Statistical Methods in Clinical Trials (2 papers). The work is most often cited by research in Economics and Econometrics (344 citations), Genetics (25 citations), Family Practice (4 citations), Physiology (57 citations) and Pharmacology (19 citations). Rick A. Vreman has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Wim Goettsch, Aukje K. Mantel‐Teeuwisse, Hubert G. M. Leufkens, Anke M. Hövels, Aaron S. Kesselheim, Joris C. Verster, Berend Olivier, Suzanne de Klerk, James G. Kahn and Travis C. Porco. Their work appears in journals such as Value in Health, International Journal of Technology Assessment in Health Care, BMJ Open, Drug Discovery Today and Clinical Pharmacology & Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.